litlas
ログインアカウント作成

Richard P. Baum

1997–2025 年に発表

111
論文数
20,509
被引用数
72
h 指数
104
i10 指数

被引用数

Richard P. Baum の年別被引用数1967 年: 被引用 1 件1984 年: 被引用 1 件1999 年: 被引用 10 件2000 年: 被引用 12 件2001 年: 被引用 24 件2002 年: 被引用 19 件2003 年: 被引用 25 件2004 年: 被引用 39 件2005 年: 被引用 27 件2006 年: 被引用 35 件2007 年: 被引用 42 件2008 年: 被引用 54 件2009 年: 被引用 61 件2010 年: 被引用 105 件2011 年: 被引用 110 件2012 年: 被引用 137 件2013 年: 被引用 99 件2014 年: 被引用 93 件2015 年: 被引用 108 件2016 年: 被引用 118 件2017 年: 被引用 241 件2018 年: 被引用 275 件2019 年: 被引用 772 件2020 年: 被引用 878 件2021 年: 被引用 956 件2022 年: 被引用 644 件2023 年: 被引用 516 件2024 年: 被引用 893 件2025 年: 被引用 386 件2026 年: 被引用 2 件1968〜1983 年は被引用が無いため表示していません1985〜1998 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,413 件、この内訳の 19.5%ドイツ: 引用元論文 934 件、この内訳の 12.9%イタリア: 引用元論文 470 件、この内訳の 6.5%オランダ: 引用元論文 421 件、この内訳の 5.8%イギリス: 引用元論文 375 件、この内訳の 5.2%中国: 引用元論文 367 件、この内訳の 5.1%フランス: 引用元論文 323 件、この内訳の 4.4%スイス: 引用元論文 317 件、この内訳の 4.4%カナダ: 引用元論文 223 件、この内訳の 3.1%オーストラリア: 引用元論文 219 件、この内訳の 3%スウェーデン: 引用元論文 201 件、この内訳の 2.8%オーストリア: 引用元論文 160 件、この内訳の 2.2%
0%19.5%その他 25.1%

機関

分野

  • Medicine92%
  • Biochemistry, Genetics and Molecular Biology3.2%
  • Neuroscience1%
  • Engineering0.9%
  • Materials Science0.8%
  • Computer Science0.4%
  • その他1.7%

トピック

  • Radiopharmaceutical Chemistry and Applications13.4%
  • Neuroendocrine Tumor Research Advances11.5%
  • Lung Cancer Research Studies7.1%
  • Prostate Cancer Treatment and Research6.8%
  • Medical Imaging Techniques and Applications6.2%
  • Neuroblastoma Research and Treatments5.2%
  • その他49.8%

共著者

全論文

検索で開く
  1. Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors

    著者: Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin, Andrew Hendifar, James C. Yao, Beth Chasen, Erik Mittra, Pamela L. Kunz, Matthew H. Kulke, Heather A. Jacene, David Bushnell, Thomas M. O’Dorisio, Richard P. Baum, Harshad Kulkarni, Martyn Caplin, Rachida Lebtahi, Timothy J. Hobday, Ebrahim S. Delpassand, Eric Van Cutsem, Al B. Benson, Rajaventhan Srirajaskanthan, Marianne Pavel, Jaime Font de Mora, Jordan Berlin, Enrique Grande, Nicholas S. Reed, Ettore Seregni, Kjell Öberg, Maribel Lopera Sierra, Paola Santoro, Thomas Thevenet, Jack L. Erion, Philippe Ruszniewski, Dik J. Kwekkeboom, Eric P. Krenning - New England Journal of Medicine 2017 被引用: 3,178

  2. Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results

    著者: Richard P. Baum, Christiane Schuchardt, Aviral Singh, Maythinee Chantadisai, F Robiller, Jingjing Zhang, Dirk Müeller, Alexander Eismant, Frankis Almaguel, Dirk Zboralski, Frank Osterkamp, Aileen Hoehne, Ulrich Reineke, Christiane Smerling, Harshad Kulkarni - Journal of Nuclear Medicine 2021 被引用: 327

  3. Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

    著者: Clemens Kratochwil, Wolfgang P. Fendler, Matthias Eiber, Michael S. Hofman, Louise Emmett, Jérémie Calais, Joseph R. Osborne, Amir Iravani, Phillip J. Koo, Liza Lindenberg, Richard P. Baum, Murat Fani Bozkurt, Roberto C. Delgado Bolton, Samer Ezziddin, Flavio Forrer, Rodney J. Hicks, Thomas A. Hope, Levent Kabasakal, Mark Konijnenberg, Klaus Kopka, Michael Laßmann, Felix M. Mottaghy, Wim J.G. Oyen, Kambiz Rahbar, Heiko Schöder, Irene Virgolini, Lisa Bodei, Stefano Fanti, Uwe Haberkorn, Ken Hermann - European Journal of Nuclear Medicine and Molecular Imaging 2023 被引用: 255

  4. German Multicenter Study Investigating177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients

    著者: Kambiz Rahbar, Hojjat Ahmadzadehfar, Clemens Kratochwil, Uwe Haberkorn, Michael Schäfers, Markus Essler, Richard P. Baum, Harshad Kulkarni, Matthias Schmidt, Alexander Drzezga, Peter Bartenstein, Andreas Pfestroff, Markus Luster, Ulf Lützen, Marlies Marx, Vikas Prasad, Winfried Brenner, Alexander Heinzel, Felix M. Mottaghy, Juri Ruf, Philipp T. Meyer, Martin Heuschkel, Maria Eveslage, Martin Bögemann, Wolfgang P. Fendler, Bernd J. Krause - Journal of Nuclear Medicine 2016 被引用: 832

  5. Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry

    著者: Christiane Schuchardt, Jingjing Zhang, Harshad Kulkarni, Xiaoyuan Chen, Dirk Müller, Richard P. Baum - Journal of Nuclear Medicine 2021 被引用: 177

  6. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies

    著者: Martina Weineisen, Margret Schottelius, Jakub Šimeček, Richard P. Baum, Akın Yıldız, Seval Beykan, Harshad Kulkarni, Michael Laßmann, Ingo Klette, Matthias Eiber, Markus Schwaiger, Hans‐Jürgen Wester - Journal of Nuclear Medicine 2015 被引用: 532

  7. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial

    著者: Jonathan Strosberg, Edward M. Wolin, Beth Chasen, Matthew H. Kulke, David Bushnell, Martyn Caplin, Richard P. Baum, Pamela L. Kunz, Timothy J. Hobday, Andrew Hendifar, Kjell Öberg, Maribel Lopera Sierra, Thomas Thevenet, Inés Margalet, Philippe Ruszniewski, Eric P. Krenning, on behalf of the NETTER-1 Study Group - Journal of Clinical Oncology 2018 被引用: 389

  8. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours

    著者: John J. Zaknun, Lisa Bodei, Jan Mueller‐Brand, Marianne E. Pavel, Richard P. Baum, Dieter Hörsch, M. Sue O’Dorisio, T. M. O’Dorisiol, James R. Howe, Marta Cremonesi, Dik J. Kwekkeboom - European Journal of Nuclear Medicine and Molecular Imaging 2013 被引用: 809

  9. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)

    著者: Clemens Kratochwil, Wolfgang P. Fendler, Matthias Eiber, Richard P. Baum, Murat Fani Bozkurt, Johannes Czernin, Roberto C. Delgado Bolton, Samer Ezziddin, Flavio Forrer, Rodney J. Hicks, Thomas A. Hope, Levent Kabasakal, Mark Konijnenberg, Klaus Kopka, Michael Laßmann, Felix M. Mottaghy, Wim J.G. Oyen, Kambiz Rahbar, Heiko Schöder, Irene Virgolini, Hans-Jürgen Wester, Lisa Bodei, Stefano Fanti, Uwe Haberkorn, Ken Herrmann - European Journal of Nuclear Medicine and Molecular Imaging 2019 被引用: 383

  10. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy

    著者: Richard P. Baum, Harshad Kulkarni, Christiane Schuchardt, Aviral Singh, Martina Wirtz, Stefan Wiessalla, Margret Schottelius, Dirk Müeller, Ingo Klette, Hans‐Jürgen Wester - Journal of Nuclear Medicine 2016 被引用: 526

  11. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors

    著者: Lisa Bodei, Mark Kidd, Giovanni Paganelli, Chiara Maria Grana, Ignat Drozdov, Marta Cremonesi, Christopher Lepensky, Dik J. Kwekkeboom, Richard P. Baum, Eric P. Krenning, Irvin M. Modlin - European Journal of Nuclear Medicine and Molecular Imaging 2014 被引用: 466

  12. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0

    著者: Ronald Boellaard, M. J. OʼDoherty, Wolfgang Weber, Felix M. Mottaghy, Markus Nowak Lonsdale, Sigrid Stroobants, Wim J.G. Oyen, Joerg Kotzerke, Otto S. Hoekstra, Jan Pruim, Paul Marsden, Klaus Tatsch, C. Hoekstra, Eric P. Visser, Bertjan Arends, Fred Verzijlbergen, Josée M. Zijlstra, Emile F.I. Comans, Adriaan A. Lammertsma, Anne M. J. Paans, Antoon T. M. Willemsen, Thomas Beyer, Andreas Bockisch, Cornelia Schaefer‐Prokop, Dominique Delbeke, Richard P. Baum, Arturo Chiti, Bernd J. Krause - European Journal of Nuclear Medicine and Molecular Imaging 2009 被引用: 1,343

  13. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)

    著者: Hojjat Ahmadzadehfar, Kambiz Rahbar, Richard P. Baum, Robert Seifert, Katharina Kessel, Martin Bögemann, Harshad Kulkarni, Jingjing Zhang, Carolin Gerke, Rolf Fimmers, Clemens Kratochwil, Hendrik Rathke, Harun Ilhan, Johanna Maffey-Steffan, Mike Sathekge, Levent Kabasakal, Francisco O. García-Pérez, Kalevi Kairemo, Masha Maharaj, Diana Páez, Irene Virgolini - European Journal of Nuclear Medicine and Molecular Imaging 2020 被引用: 129

  14. First-in-Humans Study of the SSTR Antagonist 177Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy

    著者: Richard P. Baum, Jingjing Zhang, Christiane Schuchardt, Dirk Müller, Helmut R. Mäcke - Journal of Nuclear Medicine 2021 被引用: 108

  15. Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists

    著者: Mengqi Shi, Vivianne Jakobsson, Lukas Greifenstein, Pek‐Lan Khong, Xiaoyuan Chen, Richard P. Baum, Jingjing Zhang - Frontiers in Medicine 2022 被引用: 58

  16. Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with 177Lu-PSMA and Combined 225Ac- and 177Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation

    著者: Thomas Langbein, Harshad Kulkarni, Christiane Schuchardt, Dirk Müeller, Gerd Fabian Volk, Richard P. Baum - Diagnostics 2022 被引用: 44

  17. First-in-Humans Application of 161Tb: A Feasibility Study Using 161Tb-DOTATOC

    著者: Richard P. Baum, Aviral Singh, Harshad Kulkarni, Peter Bernhardt, Tobias Rydèn, Christiane Schuchardt, Nadezda Gracheva, Pascal V. Grundler, U. Köster, Dirk Müller, Michael Pröhl, Jan Rijn Zeevaart, Roger Schibli, Nicholas P. van der Meulen, Cristina Müller - Journal of Nuclear Medicine 2021 被引用: 100

  18. Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results

    著者: Richard P. Baum, Christiane Schuchardt, Aviral Singh, Maythinee Chantadisai, F Robiller, Jingjing Zhang, Dirk Müeller, Alexander Eismant, Frankis Almaguel, Dirk Zboralski, Frank Osterkamp, Aileen Hoehne, Ulrich Reineke, Christiane Smerling, Harshad Kulkarni - 2021 被引用: 30

  19. THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka Experience

    著者: Richard P. Baum, Harshad Kulkarni - Theranostics 2012 被引用: 274

  20. Recent advances and impending challenges for the radiopharmaceutical sciences in oncology

    著者: Suzanne E. Lapi, Peter J. H. Scott, Andrew M. Scott, Albert D. Windhorst, Brian M. Zeglis, May Abdel–Wahab, Richard P. Baum, John M. Buatti, Francesco Giammarile, Ana P. Kiess, Amir Reza Jalilian, Peter Knoll, Aruna Korde, Jolanta Kunikowska, Sze Ting Lee, Diana Páez, Jean-Luc Urbain, Jingjing Zhang, Jason S. Lewis - The Lancet Oncology 2024 被引用: 64

  21. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results

    著者: Berthold A. Nock, Aikaterini Kaloudi, Emmanouil Lymperis, Athina Giarika, Harshad Kulkarni, Ingo Klette, Aviral Singh, Eric P. Krenning, Marion de Jong, Θεοδοσία Μάινα, Richard P. Baum - Journal of Nuclear Medicine 2016 被引用: 167

  22. PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest

    著者: Lisa Bodei, Mark Kidd, Aviral Singh, Wouter A. van der Zwan, Stefano Severi, Ignat Drozdov, Anna Malczewska, Richard P. Baum, Dik J. Kwekkeboom, Giovanni Paganelli, Eric P. Krenning, Irvin M. Modlin - European Journal of Nuclear Medicine and Molecular Imaging 2019 被引用: 105

  23. Injection of Botulinum Toxin for Preventing Salivary Gland Toxicity after PSMA Radioligand Therapy: an Empirical Proof of a Promising Concept

    著者: Richard P. Baum, Thomas Langbein, Aviral Singh, Mostafa Shahinfar, Christiane Schuchardt, Gerd Fabian Volk, Harshad Kulkarni - Nuclear Medicine and Molecular Imaging 2018 被引用: 94

  24. Rapid Tumor Washout of 177Lu-PSMA Radioligand in Renal Cell Carcinoma

    著者: Jingjing Zhang, Christiane Schuchardt, Xiaoyuan Chen, Richard P. Baum - Clinical Nuclear Medicine 2023 被引用: 30